ABK Biomedical Raises $35 Million in Series D Funding Led by J.P. Morgan Life Sciences

November 12, 2025
ABK Biomedical has secured $35 million in an oversubscribed Series D funding round led by J.P. Morgan Life Sciences Private Capital, with participation from existing investors. The funds will support clinical operations, commercialization of Eye90 microspheres, and expansion of manufacturing capabilities.

ABK Biomedical has raised $35 million in an oversubscribed Series D financing round led by new investor J.P. Morgan Life Sciences Private Capital, announced in a press release. Existing investors including F-Prime, Santé Ventures, Eight Roads Ventures, and an undisclosed medical device company also participated.

The funds will support the company’s ongoing clinical operations, preparation for the commercialization of its Eye90 microspheres, and further product development. Additional capital will be used to expand manufacturing and supply chain capabilities to meet future demand.

Eye90 microspheres, which have received FDA Breakthrough Device Designation, are currently being evaluated in the Route90 FDA IDE pivotal trial. The company aims to use the proceeds to advance the trial and position the product for market readiness.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

AI Funding News Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Funding

11/12
Diversis Capital Merges Genesis Automation Healthcare, Kermit, and Meperia
11/12
CampusKnot Raises $1.1 Million to Expand AI Teaching Assistant Platform
11/11
Gamma Raises $68 Million at $2.1 Billion Valuation, Surpasses $100 Million ARR
11/11
Automation Anywhere Acquires Aisera to Expand Agentic Automation Portfolio
11/11
RAAAM Memory Technologies Raises $17.5 Million to Advance Low-Power Chip Development

More from: Life Sciences

11/12
Diversis Capital Merges Genesis Automation Healthcare, Kermit, and Meperia
11/12
AI CoLab Hosts Second Annual 'AI for Health' Summit in Washington
11/12
SOPHiA GENETICS and Element Biosciences Integrate AI and Sequencing Platforms for Precision Medicine Research
11/12
Global Health Leaders Outline AI-Driven Roadmap at Future of Health Summit
11/12
CereCore Joins Oracle Partner Program to Expand Healthcare IT Services

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Governing the Future: A Strategic Framework for AI Adoption in Financial Institutions

This whitepaper explores the transformative impact of artificial intelligence on the financial industry, focusing on the governance challenges and regulatory demands faced by banks. It provides a strategic framework for AI adoption, emphasizing the importance of a unified AI approach to streamline compliance and reduce operational costs. The document offers actionable insights and expert recommendations for banks with fewer than 2,000 employees to become leaders in compliant, customer-centric AI.

Read more

You May Also Like